A review on therapeutic approaches for Hepatitis C virus infection: synthetic methods and SARs of direct acting antivirals

Abstract

This review provides risk factors that involves the modes of transmission as well as groups that are under risk of Hepatitis C virus (HCV). Moreover, lifecycle, pathogenesis and virulence of HCV is discussed. It also focuses on the prevalence of HCV worldwide as it is increasing day by day. The development of direct acting antivirals (DAAs) via total synthetic methods involves mechanisms that target NS3/4A protease, NS5A and NS5B. Also based on SAR modifications, improved selectivity, potency and efficacy of the drugs were achieved. Classification of DAA drugs involved studies of SVR based on clinical trials and highlights some combination therapy of HCV with inhibitors and other DAAs. Interestingly, DAAs proved having good clinical outcomes, if the comparison is done with therapies on interferons (IFN) that were employed beforehand. This review sums up the therapeutic approaches to eliminate Hepatitis C and the importance of synthetic methods in the development of DAAs.